Allan R. Li

2.9k total citations · 2 hit papers
7 papers, 2.3k citations indexed

About

Allan R. Li is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Organic Chemistry. According to data from OpenAlex, Allan R. Li has authored 7 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 1 paper in Organic Chemistry. Recurrent topics in Allan R. Li's work include Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Allan R. Li is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), HER2/EGFR in Cancer Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Allan R. Li collaborates with scholars based in United States. Allan R. Li's co-authors include Marc Ladanyi, Mark G. Kris, William Pao, Maureen F. Zakowski, Vincent A. Miller, Gregory J. Riely, Naiyer A. Rizvi, Ennapadam Venkatraman, DuyKhanh Pham and Yixuan Gong and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Modern Pathology.

In The Last Decade

Allan R. Li

7 papers receiving 2.2k citations

Hit Papers

Novel D761Y and Common Secondary T790M Mutations in Epide... 2006 2026 2012 2019 2006 2006 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
    2006 664 citations Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research profile →
  2. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
    2006 623 citations Gregory J. Riely, William Pao et al. Clinical Cancer Research profile →

Peers

Allan R. Li
Victoria A. Joshi United States
Michèle Beau‐Faller France
I. Wistuba United States
Teresa Morán Spain
Felice Mucilli Italy
Chan Zeng United States
Junko Tanizaki Japan
Haichuan Hu China
Adam Płużański Poland
Simon Dearden United Kingdom
Victoria A. Joshi United States
Allan R. Li
Citations per year, relative to Allan R. Li Allan R. Li (= 1×) peers Victoria A. Joshi

Countries citing papers authored by Allan R. Li

Since Specialization
Citations

This map shows the geographic impact of Allan R. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan R. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan R. Li more than expected).

Fields of papers citing papers by Allan R. Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan R. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan R. Li. The network helps show where Allan R. Li may publish in the future.

Co-authorship network of co-authors of Allan R. Li

This figure shows the co-authorship network connecting the top 25 collaborators of Allan R. Li. A scholar is included among the top collaborators of Allan R. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan R. Li. Allan R. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Marks, Jenifer L., Stephen Broderick, Qin Zhou, et al.. (2008). Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. Journal of Thoracic Oncology. 3(2). 111–116. 202 indexed citations
2.
Li, Allan R., Dhananjay Chitale, Gregory J. Riely, et al.. (2008). EGFR Mutations in Lung Adenocarcinomas. Journal of Molecular Diagnostics. 10(3). 242–248. 164 indexed citations
3.
Miller, Vincent A., Gregory J. Riely, Maureen F. Zakowski, et al.. (2008). Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. Journal of Clinical Oncology. 26(9). 1472–1478. 237 indexed citations
4.
Balak, Marissa N., Yixuan Gong, Gregory J. Riely, et al.. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research. 12(21). 6494–6501. 664 indexed citations breakdown →
5.
Riely, Gregory J., William Pao, DuyKhanh Pham, et al.. (2006). Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer Research. 12(3). 839–844. 623 indexed citations breakdown →
6.
Shia, Jinru, David S. Klimstra, Allan R. Li, et al.. (2005). Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Modern Pathology. 18(10). 1350–1356. 127 indexed citations
7.
Bhargava, Rohit, William L. Gerald, Allan R. Li, et al.. (2005). EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology. 18(8). 1027–1033. 272 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victoria A. Joshi Breakdown of academic impact, for papers by Michèle Beau‐Faller Breakdown of academic impact, for papers by I. Wistuba Breakdown of academic impact, for papers by Teresa Morán Breakdown of academic impact, for papers by Felice Mucilli Breakdown of academic impact, for papers by Chan Zeng Breakdown of academic impact, for papers by Junko Tanizaki Breakdown of academic impact, for papers by Haichuan Hu Breakdown of academic impact, for papers by Adam Płużański Breakdown of academic impact, for papers by Simon Dearden
Rankless by CCL
2026